This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 523 studies, archived under the term: "Alzheimer’s Disease"

Click here to filter this large number of results.

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer’s disease: A UK evaluation using discrete-event simulation
Background: Recommendations in the UK suggest restricting treatment of Alzheimer’s disease with cholinesterase inhibitors, on cost-effectiveness grounds, to patients with moderate cognitive decline. As the economic analyses that informed these recommendations have been the subject of debate, we sought to address the potential limitations of existing models and produce estimates of donepezil treatment cost effectiveness […]

Effects of galantamine in Alzheimer’s disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment
To evaluate the effects of galantamine withdrawal, and compare this with uninterrupted therapy, two 6-week double-blind withdrawal studies (Studies 1 and 2) were performed. These enrolled individuals who had completed one of two 3- or 5-month randomized clinical trials (parent trials) involving patients with mild to moderate Alzheimer’s disease (AD). In Study 1 (GAL-USA-11; n’723), […]

Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer’s Disease: the MEMAGE study
Background: Combined therapy of memantine and acetylcholinesterase inhibitors (AChEIs) in patients with Alzheimer’s disease (AD) may be associated with higher benefits than either monotherapy.; Objective: This retrospective multicentric study conducted in seven Italian Ambulatory Centers for Dementia assessed the efficacy and safety of memantine 20 mg/day administered for 6 months in addition to an AChEI […]

Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
Objective: To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD).; Methods: Double-blind, placebo-controlled trial at 40 academic centers (United States). Subjects with AD and Mini-Mental State Examination score 14-26 were randomized to PF-04494700 60 mg/day × 6 days, […]

Object alternation: a novel probe of medial frontal function in frontotemporal dementia
We studied behavioral variant frontotemporal dementia (bvFTD) using object alternation (OA) as a novel probe of cognition. This task was adopted from animal models and is sensitive to ventrolateral-orbitofrontal and medial frontal function in humans. OA was administered to bvFTD patients, normal controls, and a dementia control group with Alzheimer disease (AD). Two other frontal […]

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2
Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease […]

El efecto del formato de intervención individual o grupal en la estimulación cognitiva de pacientes con enfermedad de Alzheimer. = The effect of an individual or group intervention format in cognitive stimulation of patients with Alzheimer’s disease
The study aimed to verify whether the format of an individual or group intervention, applied in a multimodal cognitive stimulation program (MCSP), had an impact on progression and behavioral disturbances associated with Alzheimer’s disease patients (AD). Forty-five participants diagnosed with probable AD were randomly divided into 3 groups. The performance of both experimental groups, receiving […]

Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n – 3 fatty acid supplementation in patients with Alzheimer’s disease: the OmegAD study
Transthyretin (TTR) binds amyloid-β (Aβ) and may reduce brain Aβ, a pathological feature in Alzheimer’s disease (AD). N – 3 fatty acids (FA), docosahexaenoic (DHA), and eicosapentaenoic acid (EPA) may increase TTR transcription in rat hippocampus. We studied effects of n – 3 FA supplementation on TTR-levels in patients with AD. Outpatients were randomized to […]

Comparing the efficacy and safety of Crocus sativus L. With memantine in patients with moderate to severe Alzheimer’s disease: A double‐blind randomized clinical trial
Objectives Limited pharmacological options are available for the management of Alzheimer’s disease (AD) in severe stages. Cognitive‐enhancing properties of saffron, the dried stigma of Crocus sativus L., have been evidenced in different studies. We aimed to compare the efficacy and safety of saffron extract versus memantine in reducing cognitive deterioration of patients with moderate to […]

A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer’s dementia
Aims: The 24-week, prospective, randomized, double-blind ACTION study investigated the efficacy, safety, and tolerability of 13.3 versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer’s disease (AD).; Methods: Patients had probable AD and Mini-Mental State Examination scores ≥3-≤12. Primary outcome measures were as follows: Severe Impairment Battery (SIB) and AD Cooperative Study-Activities of […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us